Idorsia Pharmaceuticals Ltd: Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...
Santé log

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

Psoriasis is a chronic, immune-mediated skin condition driven by the IL-23/Th17 pathway, characterized by elevated CCL20 and CCR6-positive cells in affected skin. 1 There is a significant need for ...